keyword
MENU ▼
Read by QxMD icon Read
search

chronic lymphocytic leukaemia

keyword
https://www.readbyqxmd.com/read/28921160/gp2013-a-rituximab-biosimilar
#1
Hannah A Blair
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. GP2013 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA...
September 18, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28916317/presence-of-human-herpesvirus-8-hhv-8-dna-sequences-in-patients-with-lymphoproliferative-diseases-and-chronic-blood-disorders
#2
Hossein Keyvani, Mohammad Hadi Karbalaie Niya, Maryam Esghaei, Farah Bokharaei Salim, Seyed Hamid Reza Monavari
OBJECTIVE: Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi's sarcoma (KS), but it has also been associated with different hematologic malignancies, including plasmablastic lymphoma, Multicentric Castleman's disease (MCD), primary effusion lymphoma (PEL) and various atypical lymphoproliferative disorders. Patients with underlying lymphoproliferative diseases and chronic blood disorders who become infected with this virus are at risk for human malignancies. This small study reported the frequency of human herpesvirus -8 in 81 Iranian patients with lymphoproliferative disorders for estimation of possible factors affecting malignancy...
September 12, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28916312/lenalidomide-maintenance-in-high-risk-chronic-lymphocytic-leukaemia-practice-changing-study-or-hypothesis-generating-approach
#3
Davide Rossi, Adalgisa Condoluci
No abstract text is available yet for this article.
September 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28916311/lenalidomide-maintenance-after-first-line-therapy-for-high-risk-chronic-lymphocytic-leukaemia-cllm1-final-results-from-a-randomised-double-blind-phase-3-study
#4
Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart, Kathleen Jentsch-Ullrich, Steffen Dörfel, Kirsten Fischer, Clemens-Martin Wendtner, Thomas Nösslinger, Paolo Ghia, Francesc Bosch, Arnon P Kater, Hartmut Döhner, Michael Kneba, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
BACKGROUND: The combined use of genetic markers and detectable minimal residual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy. We aimed to assess lenalidomide maintenance therapy in these high-risk patients. METHODS: In this randomised, double-blind, phase 3 study (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a high risk for an early progression with at least a partial response after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minimal residual disease levels or intermediate levels combined with an unmutated IGHV gene status or TP53 alterations...
September 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28881925/appendix-4-chronic-lymphocytic-leukaemia-eupdate-published-online-27-june-2017-www-esmo-org-guidelines-haematological-malignancies
#5
(no author information available yet)
No abstract text is available yet for this article.
July 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28880625/biosimilar-monoclonal-antibodies-mabs-in-oncology
#6
Caroline Moore
Biological medicines are derived from living cells and organisms. Monoclonal antibodies (mAbs) are biological agents that are widely used to treat malignancies including non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. They are effective but expensive. The patents for many mAbs are expiring, so biosimilar medicines, which contain a version of the active ingredient of the original drug, are being developed. Biological medicines cannot be assessed in the same way as standard generic medications because they are difficult to copy and can change over time...
September 7, 2017: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/28864095/minimal-residual-disease-in-chronic-lymphocytic-leukaemia
#7
REVIEW
José Antonio García Vela, José Antonio García Marco
Minimal residual disease (MRD) assessment is an important endpoint in the treatment of chronic lymphocytic leukaemia (CLL). It is highly predictive of prolonged progression-free survival (PFS) and overall survival and could be considered a surrogate for PFS in the context of chemoimmunotherapy based treatment. Evaluation of MRD level by flow cytometry or molecular techniques in the era of the new BCR and Bcl-2 targeted inhibitors could identify the most cost-effective and durable treatment sequencing. A therapeutic approach guided by the level of MRD might also determine which patients would benefit from an early stop or consolidation therapy...
August 29, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28832948/diagnosis-of-cll-revisited-increased-specificity-by-a-modified-five-marker-scoring-system-including-cd200
#8
Thomas Köhnke, Veronika K Wittmann, Veit L Bücklein, Felix Lichtenegger, Zlatana Pasalic, Wolfgang Hiddemann, Karsten Spiekermann, Marion Subklewe
The modified Matutes score has been the basis for the diagnosis of chronic lymphocytic leukaemia (CLL) by flow cytometry for the past 15 years. To increase the specificity of the current score we systematically evaluated the diagnostic value of established as well as novel markers, such as CD200, in a large cohort of patients with untreated B-cell malignancies (n = 370). Double positivity for CD5 and CD23 was of very high value to differentiate between CLL and non-CLL cases. In addition, lack of FMC7 expression as well as CD79b expression intensity showed high sensitivity (90·4% and 92·3%) with acceptable specificity (74·4% and 76·9%)...
August 18, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28830517/assessment-of-ibrutinib-plus-rituximab-in-front-line-cll-flair-trial-study-protocol-for-a-phase-iii-randomised-controlled-trial
#9
Laura Collett, Dena R Howard, Talha Munir, Lucy McParland, Jamie B Oughton, Andy C Rawstron, Anna Hockaday, Claire Dimbleby, David Phillips, Kathryn McMahon, Claire Hulme, David Allsup, Adrian Bloor, Peter Hillmen
BACKGROUND: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective, targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS)...
August 22, 2017: Trials
https://www.readbyqxmd.com/read/28822981/spectrum-of-lymphomas-across-different-drug-treatment-groups-in-rheumatoid-arthritis-a-european-registries-collaborative-project
#10
Louise K Mercer, Anne C Regierer, Xavier Mariette, William G Dixon, Eva Baecklund, Karin Hellgren, Lene Dreyer, Merete Lund Hetland, René Cordtz, Kimme Hyrich, Anja Strangfeld, Angela Zink, Helena Canhao, M Victoria Hernandez, Florence Tubach, Jacques-Eric Gottenberg, Jacques Morel, Jakub Zavada, Florenzo Iannone, Johan Askling, Joachim Listing
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma...
August 19, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28804121/lamin-b1-regulates-somatic-mutations-and-progression-of-b-cell-malignancies
#11
T Klymenko, J Bloehdorn, J Bahlo, S Robrecht, G Akylzhanova, K Cox, S Estenfelder, J Wang, J Edelmann, J C Strefford, T K Wojdacz, K Fischer, M Hallek, S Stilgenbauer, M Cragg, J Gribben, A Braun
Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA sequence and diversify their antigen receptors. Here, we report that genome binding of Lamin B1, a component of the nuclear envelope involved in epigenetic chromatin regulation, is reduced during B-cell activation and formation of lymphoid germinal centres. Chromatin immunoprecipitation-Seq analysis showed that kappa and heavy variable immunoglobulin domains were released from the Lamin B1 suppressive environment when SHM was induced in B cells...
August 14, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28781815/preliminary-data-on-microrna-expression-profiles-in-a-group-of-south-african-patients-diagnosed-with-chronic-myeloid-leukaemia
#12
Andrea Prinsloo, Roger Pool, Chantal Van Niekerk
Micro-ribonucleic acids (miRNAs) are small functional non-coding RNAs that downregulate gene expression at the post-transcriptional level. Abnormal expression of specific miRNAs has been recorded in chronic lymphocytic leukaemia, other non-Hodgkin B-cell lymphomas, lung cancer and chronic myeloid leukaemia (CML). The aim of this study was to compare miRNA expression profiles among patients with newly diagnosed CML, those on established therapy with imatinib mesylate, and healthy individuals. The expression of 88 miRNAs was evaluated in a total of nine samples divided into three groups: Group 1 comprised three samples collected from newly diagnosed CML patients; group 2 consisted of three samples collected from patients on therapy; the remaining three samples were collected from healthy volunteers (control group)...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28771672/med12-mutations-and-notch-signalling-in-chronic-lymphocytic-leukaemia
#13
Bian Wu, Mikołaj Słabicki, Leopold Sellner, Sascha Dietrich, Xiyang Liu, Alexander Jethwa, Jennifer Hüllein, Tatjana Walther, Lena Wagner, Zhiqin Huang, Marc Zapatka, Thorsten Zenz
Mutations in the N-terminus of MED12 protein occur at high frequency in uterine leiomyomas and breast fibroepithelial tumours, and are frequently found in chronic lymphocytic leukaemia (CLL). MED12 mutations have been previously linked to aberrant Cyclin C-CDK8 kinase activity, but the exact oncogenic function in CLL is unknown. Here, we characterized MED12 mutations in CLL and identified recurrent mutations in 13 out of 188 CLL patients (6·9%), which clustered in the N-terminus. MED12 mutations were associated with unmutated IGHV (P = 0·024)...
August 2, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28762081/ibrutinib-versus-previous-standard-of-care-an-adjusted-comparison-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukaemia
#14
Lotta Hansson, Anna Asklid, Joris Diels, Sandra Eketorp-Sylvan, Johanna Repits, Frans Søltoft, Ulrich Jäger, Anders Österborg
This study explored the relative efficacy of ibrutinib versus previous standard-of-care treatments in relapsed/refractory patients with chronic lymphocytic leukaemia (CLL), using multivariate regression modelling to adjust for baseline prognostic factors. Individual patient data were collected from an observational Stockholm cohort of consecutive patients (n = 144) diagnosed with CLL between 2002 and 2013 who had received at least second-line treatment. Data were compared with results of the RESONATE clinical trial...
July 31, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28762015/using-genomic-information-to-guide-ibrutinib-treatment-decisions-in-chronic-lymphocytic-leukaemia-a-cost-effectiveness-analysis
#15
James Buchanan, Sarah Wordsworth, Ruth Clifford, Pauline Robbe, Jenny C Taylor, Anna Schuh, Samantha J L Knight
BACKGROUND: Genomic tests may improve the stratification of patients to receive new therapies in several disease areas. However, the use of expensive targeted therapies can impact on the cost effectiveness of these tests. This study presents an economic evaluation of genomic testing in chronic lymphocytic leukaemia in the context of the UK National Health Service. METHODS: Cost-effectiveness and cost-utility analyses (using life-years and quality-adjusted life-years) were undertaken from a National Health Service and societal perspective...
July 31, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28753229/rapid-decline-in-insulin-antibodies-and-glutamic-acid-decarboxylase-autoantibodies-with-ibrutinib-therapy-of-chronic-lymphocytic-leukaemia
#16
C Skrabs, W F Pickl, T Perkmann, U Jäger, A Gessl
WHAT IS KNOWN AND OBJECTIVE: Ibrutinib is inhibiting the Bruton's tyrosine kinase (BTK), thereby influencing B-cell development. We describe an unexpected side effect of ibrutinib in two patients with chronic lymphocytic leukaemia concerning the vigorous decrease of two different diabetes-associated antibodies. CASE DESCRIPTION: Two weeks after onset of ibrutinib therapy, patient A frequently noticed symptoms of hypoglycaemia such as dizziness and blurred vision...
July 28, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28752619/spectrum-and-immunophenotyping-of-653-patients-with-b-cell-chronic-lymphoproliferative-disorders-in-china-a-single-centre-analysis
#17
Yi Miao, Lei Cao, Qian Sun, Xiao-Tong Li, Yan Wang, Chun Qiao, Li Wang, Rong Wang, Hai-Rong Qiu, Wei Xu, Jian-Yong Li, Yu-Jie Wu, Lei Fan
The incidence of B-cell chronic lymphoproliferative disorders (B-CLPDs) is significantly lower in China than that in western countries. There have been studies involving small cohorts with conflicting results regarding the spectrum of B-CLPDs in China, and the types and immunophenotyping of B-CLPDs in China remain largely unexplored. We conducted a retrospective analysis of 653 cases of B-CLPDs seen in our centre from 2011 to 2015. Four-colour flow cytometry was used to determine the expression of each immunological marker, and the diagnostic values of the immunological markers were also investigated...
July 28, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28751718/two-mouse-models-reveal-an-actionable-parp1-dependence-in-aggressive-chronic-lymphocytic-leukemia
#18
Gero Knittel, Tim Rehkämper, Darya Korovkina, Paul Liedgens, Christian Fritz, Alessandro Torgovnick, Yussor Al-Baldawi, Mona Al-Maarri, Yupeng Cun, Oleg Fedorchenko, Arina Riabinska, Filippo Beleggia, Phuong-Hien Nguyen, F Thomas Wunderlich, Monika Ortmann, Manuel Montesinos-Rongen, Eugen Tausch, Stephan Stilgenbauer, Lukas P Frenzel, Marco Herling, Carmen Herling, Jasmin Bahlo, Michael Hallek, Martin Peifer, Reinhard Buettner, Thorsten Persigehl, H Christian Reinhardt
Chronic lymphocytic leukemia (CLL) remains an incurable disease. Two recurrent cytogenetic aberrations, namely del(17p), affecting TP53, and del(11q), affecting ATM, are associated with resistance against genotoxic chemotherapy (del17p) and poor outcome (del11q and del17p). Both del(17p) and del(11q) are also associated with inferior outcome to the novel targeted agents, such as the BTK inhibitor ibrutinib. Thus, even in the era of targeted therapies, CLL with alterations in the ATM/p53 pathway remains a clinical challenge...
July 28, 2017: Nature Communications
https://www.readbyqxmd.com/read/28747208/ga101-obinutuzumab-monoclonal-antibody-as-consolidation-therapy-in-cll-galactic-trial-study-protocol-for-a-phase-ii-iii-randomised-controlled-trial
#19
Jamie B Oughton, Laura Collett, Dena R Howard, Anna Hockaday, Talha Munir, Kathryn McMahon, Lucy McParland, Claire Dimbleby, David Phillips, Andy C Rawstron, Peter Hillmen
BACKGROUND: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. METHODS/DESIGN: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) is a seamless phase II/III, multi-centre, randomised, controlled, open, parallel-group trial for patients with CLL who have recently responded to chemotherapy...
July 26, 2017: Trials
https://www.readbyqxmd.com/read/28745332/impact-of-gender-on-outcome-after-chemoimmunotherapy-in-patients-with-chronic-lymphocytic-leukemia-a-meta-analysis-by-the-german-cll-study-group
#20
O Al-Sawaf, S Robrecht, J Bahlo, A M Fink, P Cramer, J von Tresckow, C Maurer, M Bergmann, T Seiler, E Lange, M Kneba, S Stilgenbauer, H Döhner, M G Kiehl, U Jäger, C M Wendtner, K Fischer, V Goede, M Hallek, B Eichhorst, G Hopfinger
No abstract text is available yet for this article.
July 12, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
68560
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"